Pacific Biosciences of California Earnings: Analysts Boost Forecasts for 2025

Pacific Biosciences of California reported Q2 earnings with revenues of $40m, a 9.0% increase from analyst forecasts. Statutory losses per share were $0.14, 9.0% lower than expected. Analysts have updated their forecasts for 2025, with revenues predicted to be $160.2m and losses per share to be $1.87. Despite upgrades, the price target remains at $2.08, with a range of analyst estimates between $1.25 and $3.00 per share.

Pacific Biosciences of California (PACB) reported its second-quarter (Q2) 2025 earnings, showing a strong performance that exceeded analyst expectations. The company reported revenues of $40.08 million, a 9.06% increase from the Zacks Consensus Estimate of $39.77 million [1]. This marks the fourth consecutive quarter where Pacific Biosciences has beaten revenue expectations.

Statutory losses per share were reported at $0.14, which is 9.0% lower than the expected $0.18 per share [1]. This quarterly report represents an earnings surprise of +27.78% [1]. The company's earnings per share (EPS) for the quarter ended June 2025 were $0.13 per share, compared to a loss of $0.2 per share a year ago, representing a significant improvement [1].

Pacific Biosciences' revenues were driven by a 10.4% year-over-year increase, with product revenue reaching $33.08 million and service and other revenue contributing $6.68 million [2]. The company's CEO, Christian Henry, highlighted the strong growth in the Revio/Vega platform in clinical and new markets, attributing the results to disciplined cost management and increased adoption of sequencing platforms [2].

Analysts have updated their forecasts for 2025, with revenues predicted to be $160.2 million and losses per share to be $1.87 [1]. Despite the upgrades, the price target remains at $2.08, with a range of analyst estimates between $1.25 and $3.00 per share [1]. The stock price of Pacific Biosciences has seen mixed performance, with a 24.6% decline since the beginning of the year compared to the S&P 500's gain of 7.9% [1].

The company's performance has been notable, with a 75.8% reduction in net losses compared to the same period a year ago [2]. Pacific Biosciences has shown resilience and growth despite operating in a challenging market, and investors are closely watching for future earnings expectations and management's commentary on the earnings call.

References:
[1] https://finance.yahoo.com/news/pacific-biosciences-california-pacb-reports-230001433.html
[2] https://www.ainvest.com/news/pacific-biosciences-2025-q2-earnings-narrowed-losses-revenue-growth-2508/